Year All2026202520242023202220212020201920182017201620152014 Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis May 22, 2026 Read More Abivax Announces Results of its May 11, 2026 Annual General Meeting May 11, 2026 Read More Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares May 05, 2026 Read More Abivax to Present Data on Obefazimod at Digestive Disease Week® April 22, 2026 Read More Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents April 20, 2026 Read More Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies April 01, 2026 Read More Abivax Announces Full Year 2025 Financial Results and Provides Business Updates March 23, 2026 Read More Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 February 21, 2026 Read More Abivax Provides 2026 Corporate Outlook January 07, 2026 Read More Abivax to be Added to Nasdaq Biotechnology Index December 18, 2025 Read More
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis May 22, 2026 Read More
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares May 05, 2026 Read More
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents April 20, 2026 Read More
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies April 01, 2026 Read More
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates March 23, 2026 Read More
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 February 21, 2026 Read More
